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This study presents a limitation regarding the subjectivity inherent to costs determi-
nation based on answers given by the HP. Moreover values may be underestimated 
due to lack of information regarding fixed costs.
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Objectives: Data on economic burden of advanced or metastatic non-small cell lung 
cancer (NSCLC) are lacking in Slovakia. Therefore, the objective of this cost of illness 
study was to measure the resource utilisation and the costs associated with treating 
advanced or metastatic NSCLC in Slovakia and provide a basis for cost-effectiveness 
evaluations. MethOds: The project was run in two phases: in the first phase an 
Expert panel took part in the survey and developed the diagnostic and treatment 
algorithms to reflect the local medical practice and quantify the use of resources 
associated with anticancer drug treatment, management of adverse events and best 
supportive care. Then, in the second step, 2012 management costs were applied to the 
resources. All types of health care used in the NSCLC management were evaluated 
(outpatient and inpatient visits, diagnostics, prescription drugs and examinations). 
The analysis was performed from the Slovakian health insurance perspective reflect-
ing direct medical costs only. The structure of cost data follows the requirements 
of pharmaco-economic modelling in NSCLC. Results: Monthly costs of advanced 
or metastatic NSCLC management during the active treatment (before progression) 
count for € 1055.67, during the disease progression € 1101.21 and on the best supporting 
care € 1561.22. The most frequent regimens were cisplatin+gemcitabine (20.6%) and 
cisplatine+pemetrexed (19.1%) in the first line, erlotinib (49.1%) in the second line and 
gemcitabine (29.6%) in the third line. The most costly side effects were renal toxic-
ity (€ 1060.85), febrile neutropenia (€ 902.92), hemoptysis (€ 717.08), anaemia (€ 668.84), 
pain (€ 631.34), leukopenia/neutropenia (€ 629.58), dyspnoe (€ 628.35), thrombocytope-
nia (€ 578.60), nausea/vomiting (€ 562.72) and fatigue (€ 523.19). cOnclusiOns: Cost-
effectiveness must be demonstrated in order to get reimbursement in Slovakia and 
local resource use data are key drivers for health economic modelling and can guide 
resource allocation decisions in NSCLC. This study provides important information 
to support these decisions.
CaNCeR – Patient-Reported outcomes & Patient Preference studies
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Objectives: It is widely thought that adherence rates to intravenous (IV) chemo-
therapy regimens for colon cancer are high. However, there are no known formal 
assessments of this issue. MethOds: A retrospective analysis was performed using 
the Optuminsight Oncology claims database. Patients aged 18 years and older, diag-
nosed with CRC between July 1, 2004 and December 31, 2010, who were insured by a 
commercial health plan were included in the study. Adherence to the following IV 
chemotherapy regimens was assessed using the National Comprehensive Cancer 
Network (NCCN) guidelines as the standard for expected cycle/regimen duration: 
FOLFOX, FOLFOX+bevacizumab, FOLFIRI, and FOLFIRI+bevacizumab. Adherence 
was assessed using the medication possession ratio (MPR), calculated as the num-
ber of days a patient was covered by their chemotherapy regimen, according to 
NCCN guidelines, divided by the number of days elapsed from the first to the last 
infusion of that regimen. Results: A total of 46,941 chemotherapy cycles in 6,880 
patients were analyzed. Overall, adherence rates to IV chemotherapy was fairly 
high, with mean MPR ranging between 0.84 and 0.88 for these regimens. However, 
a substantial proportion of patients for each regimen experienced low adherence. 
Twenty five percent of patients receiving FOLFOX, FOLFOX+bevacizumab, and 
FOLFIRI+bevacizumab regimens experienced MPR< 0.8. Additionally, approximately 
35% of patients receiving FOLFIRI experienced an MPR< 0.8. At least 10% of patients 
receiving FOLFOX regimens had an MPR less than 0.7; while at least 10% of patients 
receiving FOLFIRI regimens had an MPR of less than 0.6. cOnclusiOns: Although 
overall rates of adherence were fairly high, a substantial subpopulation experienced 
low adherence to each of these IV regimens per NCCN guideline recommendations. 
The reasons for the low adherence rates need to be explored as this could have an 
impact on efficacy. These results also highlight the drawback of relying solely on 
summary statistics at the population level.
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Objectives: Lack of non-compliance is often underestimated in breast cancer 
treatment. The aim of our study was to analyze the persistence with tamoxifen 
(TAM) and aromatase inhibitors (AI) in women with breast cancer (BC) and to 
identify reasons of treatment discontinuation and determinants of non-per-
sistency. MethOds: We used data of the Oncology Analyzer database, which 
includes individual information on patient history related to the treatment of 
patients across all cancer types. This enables a complete overview of cancer 
patient care from diagnosis onward, facilitating research in areas such as treat-
ment changesn, dosing and regimen compliance, market sizing and off-label use. 
We identified 7063 breast cancer patients with a start of TAM or AI therapy from 
1990 until 2011 and with a treatment duration of at least 365 days. Results: After 
tion). cOnclusiOns: Disability in cancer survivors is very common and is more 
severe than in other diseases.
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Objectives: To compare the possible time savings from reduction of nursing and 
pharmacy time to manage advanced esophago-gastric cancer (AEGC) patients using 
capecitabine-based regimens versus traditional 5-FU based intravenous (IV) chemo-
therapy in the Hong Kong public hospital setting. MethOds: This was a time-and-
motion study conducted in 2 public hospitals of Hong Kong based on the simulation 
of previously data on both capecitabine-based regimen (XELOX and XP) and IV 
5-FU-based regimen (FOLFOX and FP). The preparation, dispensing and administration 
time for XELOX, XP, FOLFOX and FP were compared. The capital item utilization includ-
ing hospital bed, infusion pump etc and length of patient attendance were recorded. 
Each subject was based on 24-week cycle in the analysis. The projected cost saving 
in nursing and pharmacy time was estimated if all AEGC in Hong Kong were pre-
scribed capecitabine-based regimen. Results: The average nursing time for FOLFOX 
and FP was 83.7 and 83.4 minutes versus XELOX and XP was 33.7 and 39.8 minutes 
respectively. The average pharmacy dispensing time for FOLFOX and FP was 25.3 and 
71.4 minutes versus XELOX and XP was 18.7 and 19.9 minutes respectively. The total 
time saved for each patient for a 24-week cycle in FOLFOX versus XELOX was 734.8 
minutes in nursing and 154.0 minutes in pharmacy as well as in FP versus XP was 
182 minutes in nursing and 269.2 minutes in pharmacy. Nursing and pharmacy could 
potentially spare 3.3 full time equivalent (FTE) and 1.5 FTE if all AEGC patients were 
converted to capecitabine-based chemotherapy. cOnclusiOns: Capecitabine-based 
chemotherapy regimens saved in both nursing and pharmacy time as compared to 
traditional 5-FU based IV chemotherapy in the Hong Kong public hospital setting.
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Objectives: There has been no estimate of the productivity losses associated with 
head and neck cancer (HNC) conducted using bottom-up data, or beyond prema-
ture mortality. The aim of this work is to investigate workforce participation, and 
estimate the productivity losses associated with temporary and permanent work 
absence, reduced work hours, and premature mortality in individuals with HNC in 
Ireland. MethOds: Survey data were collected from a cancer registry identified cohort 
of individuals in Ireland diagnosed with head and neck cancer between January 1994 
and December 2011. Data collected included employment status at time of diagnosis 
and workforce participation patterns following diagnosis. These data were combined 
with population-level survival estimates and national wage data to estimate the value 
of temporary and permanent work absence, reduced work hours and premature mor-
tality using a Human Capital Approach. Results: Of the survey respondents, 276 were 
in paid work at the time of diagnosis. 88% had time off following diagnosis, with 63% of 
these returning to work. The mean (median) time off work was 9 months (6 months), 
range of 0 to 65 months. Seventy percent of individuals returning to work reported 
reducing the hours they worked, by an average of 20 hours per week. Preliminary 
results show the average productivity losses per person associated with temporary 
and permanent work absence and reduced work hours are € 222,000. Productivity losses 
associated with premature mortality and the results of sensitivity analyses to test 
discount and wage growth rates will also be presented. cOnclusiOns: Head and 
neck cancer and its treatment can have a profound impact on workforce participation. 
This affects not only the individuals’ and their families, but also society in terms of 
productivity costs. These costs should be considered in economic evaluations of cancer 
treatments and health service delivery in this population.
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Objectives: Determine the costs associated with the preparation and adminis-
tration, considering the material resources (MR) consumption and time spent by 
the health care professionals (HP), of Her2 positive breast cancer treatment with 
trastuzumab intravenous (iv) and to estimate the difference compared with a subcu-
taneous (sc) formulation. MethOds: Data were collected in face to face interviews 
with the pharmacist and nurse responsible for the preparation and administration 
of trastuzumab in each hospital. The cost of the HP time was calculated by multi-
plying the value of each HP hour by the average time of each procedure; MR costs 
were determined based on the values presented in official sources or in price table 
provided by the manufacturer. Results: Five public and two private Hospitals from 
mainland Portugal, with an average of 12 patients with HER2 + breast cancer treated 
with trastuzumab iv, per week, participated in the study. The average time spent by 
the HP in trastuzumab preparation and administration was 79 minutes for iv and 18 
minutes for sc. Per treatment cycle, the estimated average overall cost of each treat-
ment was € 43.22 (HP - € 26.01; MR - € 17.21) for iv, and € 3.18 (HP - € 3.13; MR - € 0.05) for 
sc. Considering the total course of treatment (18 cycles), the treatment with tras-
tuzumab iv is estimated at € 777.96 versus € 57.19 on sc treatment. cOnclusiOns: 
Trastuzumab sc formulation would potentially allow savings of approximately € 720 
per patient, and provide an important benefit to the patients. Trastuzumab sc would 
also contribute to maximize the efficiency and effectiveness of health resources. 
